Articles tagged with Liver Tumors
Researchers at Johns Hopkins Medicine discovered a promising experimental drug combination that reduces the size of peripheral nerve sheath tumors in mice and increases survival rates. The combination blocks glutamine metabolism and purine recycling, producing a better anti-tumor response with less toxicity.
Scientists have developed a drug-eluting hydrogel that provides sustained, pH-dependent drug co-delivery and promotes anti-tumor immune responses, reducing tumor cell proliferation and growth. The treatment shows promise in treating hepatocellular carcinoma, with enhanced efficacy compared to traditional methods.
Researchers have developed a method to camouflage stem cell-derived transplants, avoiding immune rejection and tumor formation. Genetically engineered liver cells can persist in the body despite lack of immune matching, offering a potential solution to organ donor shortage.
Scientists at Nagoya University have discovered a reliable cancer marker, stromal cell-derived factor 4 (SDF-4), that detects gastric cancer with high accuracy. The protein is found in high levels even in patients with stage I gastric cancer, suggesting its potential for early detection.
A team of researchers has developed a new visualization tool combining high-speed cameras and fluorescent injection to distinguish tumor tissue from normal tissue across cancer types. The technique, known as fluorescence lifetime (FLT) imaging, achieved an accuracy of over 97% in distinguishing tumor tissue from healthy tissue.
A University of Massachusetts Amherst team demonstrates a protein antigen from a childhood vaccine can be delivered into malignant tumor cells to refocus the immune system against cancer. The bacteria-based intracellular delivering system shows promise in treating pancreatic, liver, and metastatic breast tumors.
A University of Basel study reveals that high levels of arginine drive metabolic reprogramming to promote tumor growth. The findings suggest targeting the specific arginine-binding factor for effective liver cancer treatment.
A new gene therapy study has identified microRNA-22 as a potential treatment for liver cancer, achieving better survival outcomes and reducing inflammation compared to the current FDA-approved drug lenvatinib. The treatment was administered via a single intravenous injection and showed no observable toxicity.
Researchers found all hallmarks of T cell exhaustion within six to 12 hours of tumor exposure, including dramatic changes in gene expression and chromatin accessibility. The study challenges existing ideas about how T cells become exhausted and has implications for cancer immunotherapies.
Researchers found that immune system T cells become dysfunctional or 'exhausted' within six to 12 hours of encountering a tumor, challenging existing ideas about the process. This discovery has implications for cancer immunotherapies and may lead to new targets for preventing or reversing T cell exhaustion.
A study published in Cancer Research identifies a novel mechanism by which liver cancer develops, involving the aberrant activation of the Wnt signaling pathway and the gene GREB1. The research reveals that GREB1 is responsible for integrating conflicting cellular states of differentiation and proliferation, leading to tumor promotion.
Erdafitinib achieves tumor-agnostic benefits across 16 cancer types, including urothelial, lung, and other cancers. The trial demonstrated a disease control rate of 73.7% and clinical benefit rate of 45.6%, with notable improvements in pancreatic and cholangiocarcinoma patients.
Researchers found that distant cancers alter liver function by inducing fat accumulation and inflammation in liver cells. The process involves secretion of extracellular vesicles containing fatty acids, which reprogram the liver to resemble fatty liver disease.
SpaceMarkers, a new machine learning software, can identify molecular interactions among distinct cell types in and around tumors. By analyzing spatial transcriptomics data, it reveals genes overexpressed due to cell-to-cell interactions, providing new avenues for understanding cancer progression and treatment responses.
Researchers used human liver organoids to study fibrolamellar carcinoma, a rare childhood liver cancer. They found that different genetic mutations underlie different degrees of aggressiveness in the tumors, and uncovered the probable cell-of-origin as hepatocytes.
Researchers at the University of Colorado Cancer Center have made a breakthrough in treating pancreatic cancer by combining radiation and immunotherapy. The treatment eradicates tumors while stopping the cancer from spreading, offering new hope for patients. Clinical trials are planned to further develop this therapy.
Jeong Min Lee, KSR President and professor at Seoul National University Hospital, is honored with ARRS membership. He has published over 470 scientific articles and serves on the editorial board of several publications.
Scientists have created a new method to model liver cancer tumor subtypes using CRISPR-Cas9, discovering that specific gene isoforms can lead to different cancer subtypes. This platform could help researchers develop new therapeutic interventions for treating cancer and other diseases.
The LSU Health New Orleans Louisiana Tumor Registry released the sixth report of statewide cancer incidence rates by census tract, finding that 81% of tracts met criteria for all cancers combined. Census tracts with statistically higher incidence rates were found in parishes including Orleans, Lafourche, and St. Bernard.
Researchers identified high expression of glypican-1 in primary solid tumors, correlating with poor prognosis in various cancer types. Suppression of GPC1 attenuated cancer cell proliferation, suggesting its potential as a novel diagnostic tool and target for therapy.
The use of AI is improving diagnostic accuracy for digestive cancers, but challenges in data sharing and standardization hinder its widespread application. Researchers surveyed recent applications of AI to these deadly cancers, finding that AI can automate complex processes and detect patterns not visible to humans.
Researchers have discovered a new mechanism of immune surveillance by liver-resident macrophages called Kupffer cells that prevent liver metastasis from escaping. They successfully cleared tumors in various animal models using a new method for in situ targeted expression and remodels of KCs' anti-tumor function.
Researchers discovered that combining ferroptosis induction with immune checkpoint inhibition reduces liver tumour growth and metastases, offering a promising new approach for treating liver cancer
Researchers explore CEACAM1, CEACAM5, and CEACAM6's pathological significance in cancer biology and immunology. The review highlights their interactions with pathogens and potential avenues for cancer therapy.
A recent study published in the British Journal of Surgery found that patients undergoing liver surgery fare better in higher-volume hospitals. In-hospital mortality rates were lower in these facilities, with a rate of 2.8%, compared to 3% in lower-volume hospitals.
Researchers found that primary cancer tumors have a sluggish conversion of nutrients to usable cellular energy, conserving energy for growth and metastasis. The discovery has vast implications for anti-cancer strategies, directing attention to slow energy metabolism.
Researchers found that inhibiting HSF1 signaling reduces hepatoblastoma growth and induces apoptosis, suggesting it as a viable pharmacologic target. The study also identified HSF1's role in tumor aggressiveness and its potential association with mortality.
A phase II clinical study has found that nearly 50% of patients with inoperable locally advanced liver cancer can be cured using the tri-modality therapy. The 'Reduce and Remove' approach, which combines TACE, SBRT, and immunotherapy, results in a 90% two-year survival rate with minimal side effects.
Researchers at USC Keck School of Medicine found that liver cancer cells hijack circadian clock proteins to replicate and spread. Inhibiting these proteins can prevent cancer cell multiplication and potentially improve outcomes for patients with liver cancer.
A new study has identified a potential therapy for metastatic colon cancer by targeting the molecule hyaluronan, which accumulates in tumors and shuts down immune cells that can kill tumor cells. The experimental therapy, hyaluronidase, shrinks tumors and allows immune cells to attack tumor cells.
Researchers discovered three essential amino acids - leucine, valine, and tryptophan - as potential metabolic biomarkers for HCC. The study used metabolomics to analyze the differences in tumor and non-tumor tissue metabolomes, revealing striking differences that could aid in diagnosis.
Comprehensive metabolic changes convert mature liver cells into immature progenitor cells that proliferate rapidly and develop tumors. The main causes of liver cancer are metabolic disorders and infections with hepatitis C virus and high alcohol consumption.
Researchers have discovered that targeting a specific mutation in fibrolamellar tumors can reduce tumor growth in mice, offering a promising approach to treating this nearly incurable cancer. The findings highlight the potential for novel therapies against an intractable disease.
Researchers at the University of Missouri have successfully used click chemistry to deliver radiopharmaceuticals specifically to tumors in large dogs with bone cancer, increasing effectiveness and minimizing circulation. This breakthrough could pave the way for click chemistry-based treatments for humans with cancer in the future.
Researchers at VCU Massey Cancer Center have found strong evidence for testing a novel drug in liver cancer treatment. MDA-9 inhibition may be an effective approach for hepatocellular carcinoma (HCC), with potential synergies with other therapeutics.
A randomized phase III trial shows that adding radiation therapy to systemic therapy can delay tumor progression and lengthen survival without compromising quality of life. The combination of SBRT and sorafenib appears more effective than the drug on its own.
A new Chinese Medical Journal review article elucidates the potential contributors to non-alcoholic fatty liver disease (NAFLD) progression, highlighting the role of bile acid and sphingolipid biology. Researchers summarize current understanding of NAFLD, its progression, and potential therapeutic strategies.
Researchers identified five new hepatoblastoma tumor signatures that could help predict responses to chemotherapy treatments. The study used single-cell transcriptomic techniques to analyze tumors from infants and children, providing a window into normal development and cancer.
Scientists have identified interleukin 6 as the driver of a rare form of liver cancer that develops from degenerate liver cell precursors. Blocking IL-6 reduced both tumor number and size in mice, offering potential treatment approaches against this aggressive type of cancer.
The study found an overall response rate of 57% and disease control rate of 83% in 23 patients with diverse cancer types. These results validate RET as a tissue-agnostic target with sensitivity to RET inhibition.
Researchers at TIBI developed a minimally invasive method for targeted delivery of immunotherapeutic treatments, resulting in slower tumor growth and higher activation of T-cells. The injectable gelatin biomaterial containing silicate nanoplatelets showed sustained drug release and controlled ICI delivery.
Scientists develop nanoparticles that break down physical barriers around tumors to reach cancer cells, releasing gene editing systems like CRISPR-Cas9. The new therapy effectively stops ovarian and liver tumor growth in mice.
Researchers at Cedars-Sinai Cancer have identified a novel immune checkpoint pathway that could lead to better understanding and treatment of hepatocellular carcinoma. The study suggests that blocking this pathway, combined with immunotherapy, may provide a new therapeutic strategy for liver cancer.
A proteomic study of 2,002 tumors identified 11 distinct molecular subtypes across 14 tissue-based cancer types, including breast, lung, and brain cancers. These subtypes provide new insights into the deregulated pathways and processes in tumors that make them cancerous.
Researchers engineered mini liver tumours co-cultured with endothelial cells to investigate their crosstalk. The team found that endothelial cells promote the production of CXCL1, a protein associated with poor survival outcome in liver cancer patients.
Pediatric pathologists have discovered a new, aggressive subtype of liver cancer in children, characterized by molecular features that don't fit existing classification models. The tumors are less responsive to chemotherapy and have poor outcomes, prompting the development of a diagnostic algorithm to guide specialized treatment.
A new interactive web portal, SpUR, catalogues over 1,000 splicing events found in cancers, highlighting their role in tumor development and progression. The database provides a platform for researchers to study RNA dysregulations in cancer and develop RNA-based anti-cancer drugs.
A new study from University of Gothenburg found that men with high childhood BMI are at an elevated risk of obesity-related cancer, even if their weight is normal in young adulthood. The study analyzed data from 6,565 men born between 1945 and 1961 and found a persistently increased risk of adult obesity-related cancer.
A comprehensive analysis of over 2,200 patients in Europe reveals the complexity of cholangiocarcinoma, a rare cancer often diagnosed at an advanced stage. The study highlights the need for education programs to raise awareness and improve early diagnosis, survival, and quality of life.
A team of researchers has reprogrammed the tumor microenvironment of liver cancer by using mRNA nanoparticles, restoring the function of the p53 master regulator gene. The approach increased antitumor immune responses in hepatocellular carcinoma laboratory models and shows promise for treating HCC and other cancers.
The American Society for Radiation Oncology (ASTRO) has released a new clinical guideline outlining the use of external beam radiation therapy (EBRT) to treat adult patients with primary liver cancers. The guidelines emphasize multidisciplinary care and provide evidence-based recommendations on indications, dosing, techniques, and trea...
Researchers have described a dynamic genomic landscape of tumour heterogeneity in hepatocellular carcinoma, highlighting the need for novel strategies targeting heterogeneous tumors. The study, published in National Science Review, used multi-omic data to reveal variations in genetic and transcriptomic profiles across patients.
Researchers at University of California San Diego found a way to boost innate immunity in liver cancer, making tumors highly responsive to immunotherapy. The combination of anti-PD-L1 antibody and polyIC molecule showed remarkable synergistic effects in liver tumor inhibition.
A cohort study of 165 patients with hepatitis C-related hepatocellular carcinoma found that treating the virus with direct-acting antivirals reduces tumor progression and metastasis. The study showed a 72% reduction in tumor progression and an 88% reduction in risk of death from HCC.
A new analysis of US national data finds that external-beam radiation therapy is a proven treatment option for patients with unresectable liver cancer but is rarely prescribed, with only 3.6% of patients receiving it. The study suggests that institutional and regional practice patterns play a key role in driving treatment decisions.
A new, bacteria-based system can detect cancer cells and release therapeutic drugs directly into them, leaving healthy cells intact. The technology has shown promising results in preclinical tests on mice, particularly for liver cancer.
Ablative radioembolization has been found to have a high response rate and promising survival in patients with unresectable intrahepatic cholangiocarcinoma. The study also showed that the treatment is well-tolerated, with median overall survival not reached at 30 months.
A novel mortality risk prediction method helps tailor treatment decisions and transplant needs for patients based on individual symptoms. The new tool uses a random survival forest algorithm to predict individual mortality risk curves, calculate mortality at any given time, and provide a 95% confidence interval.
A new combination treatment has shown significant tumor shrinkage and prolonged survival in patients with metastatic uveal melanoma. The treatment, which targets HDAC and PD-1 proteins, was found to work better in tumors with active BAP1 genes, a key discovery that may lead to improved survival rates.
Scientists investigated a method to enhance immunotherapy for lung cancer and found that combining it with certain chemotherapy drugs could eliminate harmful immune cells. This approach showed promising results in preclinical studies, inducing the regression of about 70% of tumors.